查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363348

多形性胶质母细胞瘤治疗市场规模、份额和趋势分析报告：2023-2030 年按治疗、药物类别、最终用途、地区和细分市场进行的预测

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

多形性胶质母细胞瘤治疗市场的成长与趋势：

Grand View Research, Inc. 的最新报告显示，到 2030 年，全球多形性胶质母细胞瘤治疗市场规模预计将达到 51 亿美元。

预计2023年至2030年年复合成长率为9.7%。该市场的推动因素是新型疗法和联合治疗的患病不断上升以及核准不断提高。

近年来，由于创新产品的推出、有利的指导方针导致大型製药企业对市场的兴趣增加以及罹患率上升，该行业经历了快速增长。例如，百时美施贵宝、CNS Pharmaceuticals 和拜耳正在开发治疗多形性胶质母细胞瘤的新产品。未来年度，这些产品可能会加剧市场上竞争公司之间的敌意。

此外，各公司正在合作开发新的治疗方法。例如，2019年10月，临床阶段生物技术公司Advaxis, Inc.宣布在多形性胶质母细胞瘤小鼠肿瘤模型中使用其Lm技术，研究、开发和商业化一种新型免疫疗法。加州。研究人员和市场参与者之间加强合作预计将支持多形性胶质母细胞瘤新型有效治疗方案的开发。

现有公司积极收购拥有研发线产品的新公司，使其产品系列多样化。例如，2019 年 5 月，默克宣布以 11 亿美元领先收购Peloton Therapeutics，使其能够获得其在研胶质母细胞瘤治疗药物 PT2977。我们相信此次收购将加强我们的产品线并提高我们未来的产生收入能力。

世界各地的政府和非政府组织正在做出各种努力，透过教育受多形性胶质母细胞瘤罹患的人们以及为研发活动和治疗筹集资金来提高人们的认识。这些配合措施预计将推动多形性胶质母细胞瘤(GBM) 的成长）预测期内的治疗市场。例如，行动讯息平台 Ping Mobile 发起了一项行动活动，以提高人们对脑肿瘤的认识。这将有助于提高人们对多形性胶质母细胞瘤的认识，并激励多形性胶质母细胞瘤研究工作的捐款。

美国脑肿瘤协会、加拿大脑肿瘤基金会和治癒脑癌基金会等组织也正在进行一系列宣传活动，以提高大众对脑肿瘤的认识。在英国，三月是脑肿瘤意识月，由脑肿瘤研究成员组织进行活动。该活动的主要目的是提高人们对脑肿瘤研究缺乏资金的认识，并帮助人们了解脑肿瘤及其治疗方法。此外，Novocure 在脑肿瘤宣传月期间开展了一系列活动，以提高对多形性胶质母细胞瘤的认识。

多形性胶质母细胞瘤治疗市场报告亮点

  • 从治疗方法来看，放射线治疗占市场主导地位，2022年销售份额为37.0%。这是由于存活率提高，因为放射线治疗通常被推荐为第一线治疗或与化疗或手术结合。
  • 按药品类别划分，其他细分市场在 2022 年占据最大销售份额。此部分包括Everolimus、皮质类固醇和 5-氨基乙酰丙酸 (5-ALA)。
  • 2022年，医院部门在多形性胶质母细胞瘤治疗市场中占据最大的收益占有率，预计在预测期内将保持主导地位。患者更喜欢医院，因为他们可以获得护理和便利。
  • 由于仿製药替Temozolomide进入市场、经济改善、老年人口增加以及医疗保健领域投资增加等多种要素，亚太地区在预测期内将录得最快的增长率，达到11.1%。
  • 北美地区占比最大，2022年为43.4%。政府对医疗保健领域发展的支持、对罕见疾病的高度认识、优质医疗设施的便利性、优惠的报销政策等是推动该地区市场成长的主要要素。

目录

第1章调查方法与范围

第2章执行摘要

第3章多形性胶质母细胞瘤治疗市场变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 产业价值链分析
    • 赎回框架
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 多形性胶质母细胞瘤治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章多形性胶质母细胞瘤治疗市场：按治疗方法估计和趋势分析

  • 多形性胶质母细胞瘤治疗市场：重点
  • 多形性胶质母细胞瘤治疗市场：2022 年和 2030 年治疗趋势和市场占有率分析
  • 外科手术
  • 放射治疗
  • 化疗
  • 标靶治疗
  • 肿瘤治疗 (TTF) 治疗
  • 免疫疗法

第5章多形性胶质母细胞瘤治疗市场：依药物类别估计与趋势分析

  • 多形性胶质母细胞瘤治疗市场：重点
  • 多形性胶质母细胞瘤治疗市场：2022 年和 2030 年药物类别趋势和市场占有率分析
  • Temozolomide
  • Bevacizumab
  • Lomustine
  • Carmustine晶圆
  • 其他的

第6章多形性胶质母细胞瘤治疗市场：依最终用途的估计与趋势分析

  • 多形性胶质母细胞瘤治疗市场：重点
  • 多形性胶质母细胞瘤治疗市场：2022 年和 2030 年最终用途趋势和市场占有率分析
  • 医院
  • 诊所
  • 门诊手术中心

第7章多形性胶质母细胞瘤治疗市场：区域估计和趋势分析

  • 区域预测
  • 按地区分類的多形性胶质母细胞瘤治疗市场：重点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第8章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Merck & Co., Inc.
    • Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Amgen, Inc.
    • Arbor Pharmaceuticals, LLC
    • Amneal Pharmaceuticals
    • Karyopharm Therapeutics, Inc.
Product Code: GVR-4-68039-527-3

Glioblastoma Multiforme Treatment Market Growth & Trends:

The global glioblastoma multiforme treatment market size is expected to reach USD 5.10 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 9.7% from 2023 to 2030. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.

In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.

Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company's Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.

Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.

Various initiatives undertaken by the governments and non-government bodies across the globe to increase awareness by educating people living with glioblastoma multiforme and raising funds for R&D activities and treatment are expected to fuel the glioblastoma multiforme (GBM) treatment market growth during the forecast period. For instance, Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps in raising awareness about glioblastoma multiforme and motivating people to donate money for glioblastoma multiforme research activities.

Organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The main aim of the campaign is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Moreover, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month.

Glioblastoma Multiforme Treatment Market Report Highlights:

  • Based on treatment, in 2020, radiation therapy dominated the market with a revenue share of 37.0% in 2022, owing to improved survival rates, as radiation therapy is most often recommended as the first line of treatment or in combination with chemotherapy and surgery
  • By drug class, the others segment accounted for the largest revenue share in 2022. The segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA)
  • The hospital segment held the largest revenue share in the glioblastoma multiforme treatment market in 2022 and is anticipated to maintain its leading position during the forecast period. Patients prefer hospitals in terms of treatment accessibility and convenience
  • Asia Pacific is expected to register the fastest growth rate of 11.1% over the forecast period, owing to various factors such as the entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector
  • North America accounted for the largest share of 43.4% in 2022. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility to quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. Drug class
    • 1.1.3. End Use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
    • 3.4.2. Market Restraint Analysis
  • 3.5. Glioblastoma Multiforme Treatment Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
  • 4.2. Glioblastoma Multiforme Treatment Market: Treatment Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Surgery
    • 4.3.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Radiation Therapy
    • 4.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Tumor Treating Field (TTF) Therapy
    • 4.7.1. Tumor treating field (TTF) therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Immunotherapy
    • 4.8.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
  • 5.2. Glioblastoma Multiforme Treatment Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Temozolomide
    • 5.3.1. Temozolomide market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Bevacizumab
    • 5.4.1. Bevacizumab market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Lomustine
    • 5.5.1. Lomustine market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Carmustine Wafers
    • 5.6.1. Carmustine Wafers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
  • 6.2. Glioblastoma Multiforme Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Clinics
    • 6.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers
    • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Glioblastoma Multiforme Treatment Market by Region: Key Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Merck & Co., Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Teva Pharmaceutical Industries Ltd.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Sun Pharmaceutical Industries Ltd.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Hoffmann-La Roche Ltd.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pfizer, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Amgen, Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Arbor Pharmaceuticals, LLC
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Amneal Pharmaceuticals
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Karyopharm Therapeutics, Inc.
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 North America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 North America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 U.S. glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Canada glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Europe glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 Europe glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Germany glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Germany glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 UK glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 UK glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 France glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Italy glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Italy glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Spain glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Spain glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Sweden glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Sweden glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Sweden glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Norway glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 Norway glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Norway glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Denmark glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Denmark glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Denmark glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 44 China glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 China glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 China glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Japan glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Japan glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 India glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 India glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Thailand glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Thailand glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Thailand glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 South Korea glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 South Korea glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Australia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Australia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Australia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 Latin America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Latin America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Latin America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Brazil glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Brazil glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 70 Mexico glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 Mexico glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 74 Argentina glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 81 South Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 87 UAE glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 90 Kuwait glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Glioblastoma multiforme treatments: Market outlook
  • Fig. 9 Glioblastoma multiforme treatments: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Glioblastoma multiforme treatments market driver impact
  • Fig. 15 Glioblastoma multiforme treatments market restraint impact
  • Fig. 16 Glioblastoma multiforme treatments market strategic initiatives analysis
  • Fig. 17 Glioblastoma multiforme treatments market: Treatment movement analysis
  • Fig. 18 Glioblastoma multiforme treatments market: Treatment outlook and key takeaways
  • Fig. 19 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Tumor treating field (TTF) therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Immunotherapy therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Glioblastoma multiforme treatments market: Drug class movement analysis
  • Fig. 26 Glioblastoma multiforme treatments market: Drug class outlook and key takeaways
  • Fig. 27 Temozolomide market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Bevacizumab market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Lomustine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Carmustine wafers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Glioblastoma multiforme treatments market: End-use movement analysis
  • Fig. 33 Glioblastoma multiforme treatments market: End-use outlook and key takeaways
  • Fig. 34 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Ambulatory Surgical Centers market estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Global glioblastoma multiforme treatments market: Regional movement analysis
  • Fig. 38 Global glioblastoma multiforme treatments market: Regional outlook and key takeaways
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)